Skip to content
OpenCapital
Get started

CorMedix CRMD Enterprise value

Enterprise value at other companies

Pfizer logo
PfizerPFE
$222.4B+9.2%
Merck & Co. logo
Merck & Co.MRK
$341.11B+34.2%
Merit Medical Systems logo
Merit Medical SystemsMMSI
$4.43B-33.3%
ITG
Integer HoldingsITGR
$4.4B-19.6%
IAR
Integra LifeSciencesIART
$2.47B-26.7%
Emergent Biosolutions logo
Emergent BiosolutionsEBS
$851.75M+8.6%

Other financials

Income statement

See full
Revenue$127.4M+226%
Gross profit$115.4M+207%
Operating income$63.7M+216%
Net income$38.6M+87.0%
EPS (diluted)$0.43+43.3%

Balance sheet

See full
Cash & equivalents$179.1M+170%
Total debt$4.3M+729%
Total equity$437.0M+280%
Total assets$815.6M+445%

Cash flow

See full
Operating cash flow$42.4M+115%
CapEx$729.0K+7,190%
Free cash flow$41.7M+111%

Valuation

See full
Market cap$605.65M-34.4%
P/E3.4×—
P/S1.5×-9.6×

Profitability

See full
Gross margin91.9%-3.5pp
Operating margin48.4%—
Net margin45.2%—
FCF margin48.7%+38.8pp

Returns & leverage

See full
Return on equity65.6%—
Debt / equity0×0.0×
Current ratio3×-1.2×

Where this comes from

Calculated from CorMedix’s reported figures.

$916.3Mmarket cap+$4.3Mtotal debt−$145.8Mcash and equivalents=$774.78M

The official record: CorMedix’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about CorMedix's enterprise value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CorMedix's enterprise value?
CorMedix (CRMD) reported enterprise value of $774.78M in Q4 2025.
How has CorMedix's enterprise value changed year-over-year?
CorMedix's enterprise value increased by 71.7% year-over-year, from $451.25M to $774.78M.
What is the long-term trend for CorMedix's enterprise value?
Over 5 years (2020 to 2025), CorMedix's enterprise value has grown at a 26.2% compound annual growth rate (CAGR), from $241.92M to $774.78M.
What does enterprise value mean?
Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.